Panel of MicroRNAs Differentiates Uncomplicated and Severe Malaria in Children
|
By LabMedica International staff writers Posted on 25 Jan 2021 |

Image: Blood smear from a P. falciparum culture: several red blood cells have ring stages inside them while close to the center is a schizont and on the left a trophozoite (Photo courtesy of Wikimedia Commons)
MicroRNAs (miRNAs), which are rapidly released from damaged tissues into the host fluids, constitute a promising biomarker for the prognosis of severe malaria.
MiRNAs comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia and cardiovascular conditions.
Investigators at the Barcelona Institute for Global Health (Spain) postulated that miRNA levels in plasma would be expressed differentially among children with severe and uncomplicated malaria due to parasite sequestration in vital organs of severely ill children. A characteristic of severe malaria is the sequestration of Plasmodium falciparum infected red blood cells in vital organs such as the lungs, kidneys, or brain. Resulting organ damage triggers the release of miRNAs into body fluids, including the blood.
To prove their hypothesis, the investigators used advanced sequencing techniques to identify miRNAs released by human brain endothelial cells growing in culture when the cultures were exposed to red blood cells infected by P. falciparum. They then applied next-generation sequencing to evaluate the differential expression of these miRNAs in severe malaria (SM) and in uncomplicated malaria (UM) in children living in Mozambique.
Results revealed that six miRNAs were associated with in vitro P. falciparum cytoadhesion, severity in children, and P. falciparum biomass. The six miRNAs were found to be elevated in children with severe malaria. One of the miRNAs was positively related to the amount of a parasite-derived protein HRP2 (histidine rich protein 2). Previous studies had found that the concentration of HRP2 could be used to quantify growth of the parasite in vitro and to define severe malaria in patients.
"We hypothesized that miRNA levels in plasma would be differently expressed in children with severe and uncomplicated malaria, due to parasite sequestration in vital organs," said senior author Dr. Alfredo Mayor, an associate research professor at the Barcelona Institute for Global Health."Our results indicate that the different pathological events in severe and uncomplicated malaria lead to differential expression of miRNAs in plasma. These miRNAs could be used as prognostic biomarkers of disease, but we need larger studies to validate this."
The malaria microRNA study was published in the February 2021 online edition of the journal Emerging Infectious Diseases.
Related Links:
Barcelona Institute for Global Health
MiRNAs comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia and cardiovascular conditions.
Investigators at the Barcelona Institute for Global Health (Spain) postulated that miRNA levels in plasma would be expressed differentially among children with severe and uncomplicated malaria due to parasite sequestration in vital organs of severely ill children. A characteristic of severe malaria is the sequestration of Plasmodium falciparum infected red blood cells in vital organs such as the lungs, kidneys, or brain. Resulting organ damage triggers the release of miRNAs into body fluids, including the blood.
To prove their hypothesis, the investigators used advanced sequencing techniques to identify miRNAs released by human brain endothelial cells growing in culture when the cultures were exposed to red blood cells infected by P. falciparum. They then applied next-generation sequencing to evaluate the differential expression of these miRNAs in severe malaria (SM) and in uncomplicated malaria (UM) in children living in Mozambique.
Results revealed that six miRNAs were associated with in vitro P. falciparum cytoadhesion, severity in children, and P. falciparum biomass. The six miRNAs were found to be elevated in children with severe malaria. One of the miRNAs was positively related to the amount of a parasite-derived protein HRP2 (histidine rich protein 2). Previous studies had found that the concentration of HRP2 could be used to quantify growth of the parasite in vitro and to define severe malaria in patients.
"We hypothesized that miRNA levels in plasma would be differently expressed in children with severe and uncomplicated malaria, due to parasite sequestration in vital organs," said senior author Dr. Alfredo Mayor, an associate research professor at the Barcelona Institute for Global Health."Our results indicate that the different pathological events in severe and uncomplicated malaria lead to differential expression of miRNAs in plasma. These miRNAs could be used as prognostic biomarkers of disease, but we need larger studies to validate this."
The malaria microRNA study was published in the February 2021 online edition of the journal Emerging Infectious Diseases.
Related Links:
Barcelona Institute for Global Health
Latest Microbiology News
- Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
- New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
- TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
- New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
Channels
Clinical Chemistry
view channel
Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more
New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
Louse-borne relapsing fever is a neglected infection caused by Borrelia recurrentis and spread by body lice, with untreated mortality reaching up to 20%. Recurrent febrile episodes complicate recognition... Read more
TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read morePathology
view channel
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Partnership Expands Ultrasensitive Blood-Based Diagnostics for Hematologic Malignancies
Predicta Biosciences (Cambridge, MA, USA) and CIMA LAB Diagnostics at Clínica Universidad de Navarra (Pamplona, Spain) have entered an agreement to provide a joint service that combines CIMA LAB’s flow... Read more








